MDM2 and acute myeloid leukemia: For instance, aberrant recruitment of histone deacetylases (HDACs) and overexpression of heat shock proteins (Hsps) have been shown to be involved in the molecular pathogenesis and therapy response of AML [20,21], and could therefore be considered as potential therapeutic targets to combine with MDM2 inhibition.